222 related articles for article (PubMed ID: 25751688)
1. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor C; Wonder M
Aust Health Rev; 2015 Sep; 39(4):455-461. PubMed ID: 25751688
[TBL] [Abstract][Full Text] [Related]
2. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
3. Author reply: exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor CB; Wonder M
Aust Health Rev; 2016 Feb; 40(1):120. PubMed ID: 26254890
[No Abstract] [Full Text] [Related]
4. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
Sinha Y; Brien JA; Craig JC
J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
[TBL] [Abstract][Full Text] [Related]
5. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
Wonder MJ; Neville AM; Parsons R
Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
[TBL] [Abstract][Full Text] [Related]
6. Comparing the reimbursement of new medicines between Australia and New Zealand.
Ragupathy R; Babar ZU
Aust Health Rev; 2016 Feb; 40(1):118-119. PubMed ID: 26189014
[No Abstract] [Full Text] [Related]
7. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
8. Response to PHARMAC on Access to new medicines in New Zealand compared to Australia.
Milne R; Wonder M
N Z Med J; 2011 Dec; 124(1347):91-3. PubMed ID: 22237576
[No Abstract] [Full Text] [Related]
9. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
Robertson J; Walkom EJ; Bevan MD; Newby DA
BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
[TBL] [Abstract][Full Text] [Related]
10. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
11. Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand.
Evans J; Laking G; Strother M; Wang T; Metcalfe S; Blick G; Pauls R; Crausaz S
Semin Oncol; 2016 Dec; 43(6):625-637. PubMed ID: 28061980
[TBL] [Abstract][Full Text] [Related]
12. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
13. "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agency.
Davis P
Aust Health Rev; 2004 Nov; 28(2):171-81. PubMed ID: 15527397
[TBL] [Abstract][Full Text] [Related]
14. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
15. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.
Turkstra E; Bettington E; Donohue ML; Mervin MC
Int J Technol Assess Health Care; 2017 Jan; 33(4):521-528. PubMed ID: 28703092
[TBL] [Abstract][Full Text] [Related]
16. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
17. Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand.
Rawson NSB
Front Public Health; 2020; 8():544835. PubMed ID: 33194946
[No Abstract] [Full Text] [Related]
18. Financial costs associated with monopolies on biologic medicines in Australia.
Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
[TBL] [Abstract][Full Text] [Related]
19. Uptake of new medicines in New Zealand: evidence of a waiting list.
Barber JM; Sheehy KP
N Z Med J; 2015 Apr; 128(1412):10-20. PubMed ID: 25899488
[TBL] [Abstract][Full Text] [Related]
20. Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.
Grover P; Babar ZU; Oehmen R; Vitry A
Health Policy; 2018 Mar; 122(3):243-249. PubMed ID: 29295745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
